Patents by Inventor Mikael Sellén

Mikael Sellén has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prodrugs of thrombin inhibitors
    Patent number: 7354905
    Abstract: There is provided compounds of formula I, R1O(O)C—CH2—(R)Cgl-Aze-Pab-R2I wherein R1 and R2 have meanings given in the description, which are useful as prodrugs of inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (eg thrombosis) or as anticoagulants.
    Type: Grant
    Filed: February 12, 2004
    Date of Patent: April 8, 2008
    Assignee: AstraZeneca AB
    Inventors: Thomas Antonsson, David Gustafsson, Kurt-Jürgen Hoffmann, Jan-Erik Nyström, Henrik Sörensen, Mikael Sellén
  • Prodrugs of thrombin inhibitors
    Publication number: 20040162410
    Abstract: There is provided compounds of formula I,
    Type: Application
    Filed: February 12, 2004
    Publication date: August 19, 2004
    Applicant: AstraZeneca AB
    Inventors: Thomas Antonsson, David Gustafsson, Kurt-Jurgen Hoffmann, Jan-Erik Nystrom, Henrik Sorensen, Mikael Sellen
  • Prodrugs of thrombin inhibitors
    Publication number: 20020142968
    Abstract: There is provided compounds of formula I,
    Type: Application
    Filed: February 14, 2002
    Publication date: October 3, 2002
    Applicant: AstraZeneca AB
    Inventors: Thomas Antonsson, David Gustafsson, Kurt-Jurgen Hoffmann, Jan-Erik Nystrom, Henrik Sorensen, Mikael Sellen
  • Prodrugs of thrombin inhibitors
    Patent number: 6262028
    Abstract: There is provided compounds of formula I, R1O(O)C—CH2—(R)Cgl—Aze—Pab—R  I wherein R1 and R2 have meanings given in the description, which are useful as prodrugs of inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (eg thrombosis) or as anticoagulants.
    Type: Grant
    Filed: July 15, 1999
    Date of Patent: July 17, 2001
    Assignee: AstraZeneca AB
    Inventors: Thomas Antonsson, David Gustafsson, Kurt-Jürgen Hoffmann, Jan-Erik Nyström, Henrik Sörensen, Mikael Sellén
  • Prodrugs of thrombin inhibitors
    Patent number: 5965692
    Abstract: There is provided compounds of formula I,R.sup.1 O(O)C--CH.sub.2 --(R)Cgl-Aze-Pab-R.sup.2 Iwherein R.sup.1 and R.sup.2 have meanings given in the description, which are useful as prodrugs of inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (eg thrombosis) or as anticoagulants.
    Type: Grant
    Filed: January 31, 1997
    Date of Patent: October 12, 1999
    Assignee: Astra AB
    Inventors: David Gustafsson, Jan-Erik Nystrom, Henrik Sorensen, Mikael Sellen
  • Process for the production of cyclic sulfonium salts
    Patent number: 5525736
    Abstract: A process for the production of a 5-7 membered ring cyclic sulfonium salt compound, including a 5-7 membered ring cyclic sulfonium salt compound having a non-nucleophilic anion, is described. Members of the latter group are potentially useful as initiators for cationic polymerizations. The process comprises reacting a 1.4-, 1.5-, or 1.6-diol compound or a 5-7 membered ring cyclic ether compound with a mercapto compound and a strong protonic acid yielding the cyclic sulfonium salt compound. Some compounds described are also novel compounds per se.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: June 11, 1996
    Assignee: Ciba-Geigy Corporation
    Inventors: Jan-Erik Nystrom, Per Engelhardt, Katarina Beierlein, Mikael Sellen, Bjorn Elman, Jan Vagberg, Martin Nylof